Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert B. Johnson is active.

Publication


Featured researches published by Robert B. Johnson.


Journal of Virology | 2002

Oligomerization and Cooperative RNA Synthesis Activity of Hepatitis C Virus RNA-Dependent RNA Polymerase

Q.May Wang; Michelle A. Hockman; Kirk A. Staschke; Robert B. Johnson; Katharine A. Case; Jirong Lu; Steve Parsons; Faming Zhang; Radhakrishnan Rathnachalam; Karla Kirkegaard; Joseph M. Colacino

ABSTRACT The NS5B RNA-dependent RNA polymerase encoded by hepatitis C virus (HCV) plays a key role in viral replication. Reported here is evidence that HCV NS5B polymerase acts as a functional oligomer. Oligomerization of HCV NS5B protein was demonstrated by gel filtration, chemical cross-linking, temperature sensitivity, and yeast cell two-hybrid analysis. Mutagenesis studies showed that the C-terminal hydrophobic region of the protein was not essential for its oligomerization. Importantly, HCV NS5B polymerase exhibited cooperative RNA synthesis activity with a dissociation constant, Kd , of ≈22 nM, suggesting a role for the polymerase-polymerase interaction in the regulation of HCV replicase activity. Further functional evidence includes the inhibition of the wild-type NS5B polymerase activity by a catalytically inactive form of NS5B. Finally, the X-ray crystal structure of HCV NS5B polymerase was solved at 2.9 Å. Two extensive interfaces have been identified from the packing of the NS5B molecules in the crystal lattice, suggesting a higher-order structure that is consistent with the biochemical data.


Journal of Virology | 2003

Identification of a C-Terminal Regulatory Motif in Hepatitis C Virus RNA-Dependent RNA Polymerase: Structural and Biochemical Analysis

Vincent J.-P. Lévêque; Robert B. Johnson; Stephen Parsons; Jianxin Ren; Congping Xie; Faming Zhang; Q.May Wang

ABSTRACT The NS5B RNA-dependent RNA polymerase encoded by the hepatitis C virus (HCV) is a key component of the viral replicase. Reported here is the three-dimensional structure of HCV NS5B polymerase, with the highlight on its C-terminal folding, determined by X-ray crystallography at 2.1-Å resolution. Structural analysis revealed that a stretch of C-terminal residues of HCV NS5B inserted into the putative RNA binding cleft, where they formed a hydrophobic pocket and interacted with several important structural elements. This region was found to be conserved and unique to the RNA polymerases encoded by HCV and related viruses. Through biochemical analyses, we confirmed that this region interfered with the binding of HCV NS5B to RNA. Deletion of this fragment from HCV NS5B enhanced the RNA synthesis rate up to ∼50-fold. These results provide not only direct experimental insights into the role of the C-terminal tail of HCV NS5B polymerase but also a working model for the RNA synthesis mechanism employed by HCV and related viruses.


Bioorganic & Medicinal Chemistry Letters | 2003

Synthesis and evaluation of tripeptidyl α-Ketoamides as human rhinovirus 3C protease inhibitors

Shu-Hui Chen; Jason Lamar; Frantz Victor; Nancy June Snyder; Robert B. Johnson; Beverly A. Heinz; Mark Wakulchik; Q.May Wang

Abstract We describe herein the synthesis and biological evaluation of a series of tripeptidyl α-ketoamides as human rhinovirus (HRV) 3C protease inhibitors. The most potent inhibitor discussed in this manuscript, 4I, exhibited impressive enzyme inhibitory activity as well as antiviral activity against HRV-14.


Bioorganic & Medicinal Chemistry Letters | 1997

Inhibition of human rhinovirus 3C protease by homophthalimides

Louis Nickolaus Jungheim; Jeffrey Daniel Cohen; Robert B. Johnson; Elcira C. Villarreal; Mark Wakulchik; Richard J. Loncharich; Q.May Wang

Abstract Homophthalimides 2a and 3a were found to be inhibitors of Rhinovirus 3C protease through a blind screening effort. SAR studies resulted in compound 3g, which exhibited improved enzyme inhibition, in addition to whole cell antiviral activity. Molecular modeling studies suggest a preferred enzyme/inhibitor interaction, and LC/MS experiments confirmed tight/covalent binding of 3g to the enzyme.


Journal of Biological Chemistry | 1999

Identification and Characterization of Human Rhinovirus-14 3C Protease Deamidation Isoform

Gregory A. Cox; Robert B. Johnson; James A. Cook; Mark Wakulchik; Melvin G. Johnson; Elcira C. Villarreal; Q.May Wang

A purified recombinant human rhinovirus-14 3C protease preparation contained only ∼50% active enzyme as titrated using specifically designed irreversible 3C protease inhibitors. Analysis of the purified 3C protein by isoelectric focusing showed differently charged 3C isoforms that had isoelectric points (pI) of 8.3 (55%) and 9.0 (45%), with the latter one being consistent with the predicted pI of the human rhinovirus-14 3C protein. Further analysis indicated that the pI 8.3 protein was the deamidated form of 3C, and it displayed ∼10-fold reduced cleavage activity relative to the original 3C protease sample. Peptide mapping followed by sequence analysis revealed that a single asparagine, Asn-164, was deamidated to aspartic acid in the pI 8.3 isoform. Converting Asn-164 to Asp by site-directed mutagenesis resulted in a mutated 3C protease with extremely low activity, as seen with the pI 8.3 isoform, indicating a role of Asn-164 in substrate recognition and binding. In addition, the deamidated 3C protease was found to be present in vivo, and its abundance was related to the viral replication cycle. Moreover, mutant virus carrying Asp-164 showed reduced viability in infected cells. Taken together, our data suggest that 3C protein deamidation plays a role in the regulation of its enzymatic activity.


Biochemical and Biophysical Research Communications | 2000

De Novo RNA Synthesis Catalyzed by HCV RNA-Dependent RNA Polymerase

Xin-Lai Sun; Robert B. Johnson; Michelle A. Hockman; Q.May Wang


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor

Yvonne Yip; Frantz Victor; Jason Lamar; Robert B. Johnson; Q.May Wang; Donna Barket; John Irvin Glass; Ling Jin; Lifei Liu; Daryl Venable; Mark Wakulchik; Congping Xie; Beverly A. Heinz; Elcira C. Villarreal; Joe Colacino; Nathan Yumibe; Mark Joseph Tebbe; John E. Munroe; Shu-Hui Chen


Bioorganic & Medicinal Chemistry Letters | 2004

P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-ketoamides as HCV protease inhibitors

Yvonne Yip; Frantz Victor; Jason Lamar; Robert B. Johnson; Q.May Wang; John Irvin Glass; Nathan Yumibe; Mark Wakulchik; John E. Munroe; Shu-Hui Chen


Clinical Cancer Research | 2002

Phase I Trial of the Cryptophycin Analogue LY355703 Administered as an Intravenous Infusion on a Day 1 and 8 Schedule Every 21 Days

James P. Stevenson; Weijing Sun; Maryann Gallagher; Robert B. Johnson; David J. Vaughn; Lynn M. Schuchter; Kenneth Algazy; Stephen M. Hahn; Nathan Enas; Diane Ellis; Donald Thornton; Peter J. O'Dwyer


Bioorganic & Medicinal Chemistry Letters | 2004

P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α-ketoamide based HCV protease inhibitors

Frantz Victor; Jason Lamar; Nancy June Snyder; Yvonne Yip; Deqi Guo; Nathan Yumibe; Robert B. Johnson; Q.May Wang; John Irvin Glass; Shu-Hui Chen

Collaboration


Dive into the Robert B. Johnson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge